Your session is about to expire
← Back to Search
Nivolumab for Glioblastoma
Study Summary
This trial is testing whether the combination of two drugs, nivolumab and BMS-986016, can help people with glioblastoma brain tumors that have returned.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 541 Patients • NCT02041533Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have previously received an organ or tissue transplant.You have a bleeding disorder that cannot be fixed before surgery or other medical conditions that would make surgery unsafe. This includes lung or heart problems that would make it risky to use anesthesia, as well as severe problems with your immune system.You have previously received treatment with certain types of immunotherapy drugs that target specific pathways in your immune system.You are currently taking another medicine to treat glioblastoma.You have a specific type of lymphoma that starts in the central nervous system.You have a serious infection that needs strong medicines to treat it, and you started taking these medicines less than a week ago.You are willing to have an operation on your brain.You have a type of brain tumor called glioblastoma that can be treated with surgery.
- Group 1: 1
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this research the pioneering effort of its kind?
"At this moment, Nivolumab has 719 active clinical trials in 49 countries and 2357 cities. Ono Pharmaceutical Co. Ltd started the first trial for this immunotherapy drug back in 2012; it involved 659 patients and successfully finished Phases 1 & 2 of approval testing. Subsequently, 252 additional studies have been completed thus far."
What medical conditions are usually managed by administering Nivolumab?
"Nivolumab is a powerful treatment for malignant neoplasms, with applications in the management of unresectable melanoma, squamous cell carcinoma and metastatic esophageal adenocarcinoma."
Could you please elucidate any additional research conducted on Nivolumab?
"Currently, 719 research projects exploring Nivolumab are actively running. Of these studies, 82 have already progressed to Phase 3 trials. While a majority of the investigations involving this treatment are based out of Zürich, BE, there are 40364 sites around the world engaging in related research."
What are the potential hazards associated with ingesting Nivolumab?
"Given the limited clinical data surrounding nivolumab, our team of experts assigned it a rating of 1. This signifies that this drug is currently undergoing Phase 1 trials which assess its safety and efficacy."
How many participants is this research project accepting at present?
"Affirmative. Records hosted on clinicaltrials.gov demonstrate that this experiment, which was initially posted on September 24th 2018, is presently seeking participants. Approximately 20 patients must be recruited from 1 medical facility."
Are there opportunities still available to join this experimental trial?
"Affirmative. Data hosted on clinicaltrials.gov confirms that this medical study, which was initially posted in September of 2018, is actively recruiting patients. A total of 20 people will be accepted from a single location to participate in the trial."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger